Proceedings of the National Academy of Sciences · 2008 · 77 citations · 24 references
MedicineNuclear MedicineOncologyBiomedical ImagingMolecular ImagingMolecular OncologyOncologic Nuclear ImagingTargeted Cancer TherapyTargeted Imaging AgentsTargeted TherapyTherapy Response AssessmentTumor ImagingDrug Response MonitoringLigand-directed DeliveryMolecular Imaging Of CancerMolecular Target ImagingMolecular Targeting LigandsSoft Tissue Sarcoma TreatmentTarget Expression ImagingTargeted Molecular Imaging Agents
Human sarcomas are rare but diverse malignant tumors derived from mesenchymal tissue. Clinical response to therapy is currently determined by the modified World Health Organization (WHO) criteria or the Response Evaluation Criteria in Solid Tumors (RECIST), but these standards correlate poorly with sarcoma patient outcome. We introduced ligand-directed particles with elements of AAV and phage (AAVP) to enable integration of tumor targeting to molecular imaging. We report drug-response monitoring and prediction in a nude rat model of human sarcoma by AAVP imaging. As a proof-of-concept, we imaged Herpes simplex thymidine kinase in a clinic-ready setting with PET to show that one can a priori predict tumor response to a systemic cytotoxic. Given the target expression in patient-derived sarcomas, this platform may be translated in clinical applications. Sarcoma-specific ligands and promoters may ultimately lead to an imaging transcriptome.
24
Reporting results of cancer treatment
A. B. Miller, Barth Hoogstraten, M. Staquet et al. · Cancer · 1981 · 7.9K citations
Haesun Choi, C Charnsangavej, Silvana C. Faria et al. · Journal of Clinical Oncology · 2007 · 1.5K citations · Full text
Medicine, Nuclear Medicine, Oncology +17
Anti-cancer activity of targeted pro-apoptotic peptides
H. Michael Ellerby, Wadih Arap, Lisa Ellerby et al. · Nature Medicine · 1999 · 930 citations